COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology
Male
Cancer Research
Lymphoma
Epidemiology
Cardiorespiratory Medicine and Haematology
COVID-19; Pandemic; Hematological malignancies; Epidemiology; EHA
Hematological malignancies
:Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores]
0302 clinical medicine
Risk Factors
Malalties - Factors de risc
Medicine and Health Sciences
80 and over
:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]
03.02. Klinikai orvostan
Registries
Sang - Malalties - Complicacions
RC254-282
Cancer
BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.
Aged, 80 and over
COVID-19; EHA; Epidemiology; Hematological malignancies; Pandemic
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]
Hematology
Middle Aged
CANCER
3. Good health
Europe
Hospitalization
Intensive Care Units
Oncology
Hematologic Neoplasms
[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Female
BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Infektologija.
Life Sciences & Biomedicine
Adult
Oncology and Carcinogenesis
610
COVID-19; EHA; Epidemiology; Hematological malignancies; Pandemic; Adult; Aged; Aged, 80 and over; COVID-19; Europe; Female; Hematologic Neoplasms; Hospitalization; Humans; Intensive Care Units; Male; Middle Aged; Registries; Risk Factors; SARS-CoV-2; Young Adult
:técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS]
Young Adult
03 medical and health sciences
Rare Diseases
[SDV.CAN] Life Sciences [q-bio]/Cancer
616
Humans
Diseases of the blood and blood-forming organs
:neoplasias::neoplasias por localización::neoplasias hematológicas [ENFERMEDADES]
Molecular Biology
BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.
COVID-19 ; pandemic ; hematological malignancies ; epidemiology ; EHA
Aged
Science & Technology
Pandemic
SARS-CoV-2
Prevention
Research
COVID-19
EPICOVIDEHA working group
:Neoplasms::Neoplasms by Site::Hematologic Neoplasms [DISEASES]
BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Infectology.
Settore MED/15 - MALATTIE DEL SANGUE
EHA
Good Health and Well Being
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie
COVID-19 (Malaltia) - Diagnòstic
:Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT]
RC633-647.5
:Other subheadings::Other subheadings::/complications [Other subheadings]
DOI:
10.1186/s13045-021-01177-0
Publication Date:
2021-10-14T14:52:04Z
AUTHORS (196)
ABSTRACT
Abstract
Background
Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality.
Methods
The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020.
Results
The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases.
Conclusions
This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However, improved COVID-19 prevention has reduced mortality despite an increase in the number of reported cases.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (30)
CITATIONS (225)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....